How to buy Constellation Pharmaceuticals stock (CNST)

Constellation Pharmaceuticals is a biotechnology business based in the US. Constellation Pharmaceuticals shares (CNST) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.81 – an increase of 1.9% over the previous week. Constellation Pharmaceuticals employs 154 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Constellation Pharmaceuticals stock

Buy Constellation Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Constellation Pharmaceuticals stock price (NASDAQ: CNST)

Use our graph to track the performance of CNST stocks over time.

Constellation Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-09-12.

Latest market close	$19.81
52-week range	$0.00 - $0.00
50-day moving average more info button	$33.82
200-day moving average more info button	$28.33
Wall St. target price	$40.71
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.04

Is it a good time to buy Constellation Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Constellation Pharmaceuticals price performance over time

Historical closes compared with the close of $19.81 from 2021-05-28

1 week (2024-09-29)	N/A
1 month (2024-09-06)	N/A
3 months (2024-07-06)	N/A
6 months (2024-04-06)	N/A

1 year (2023-10-06)	N/A
2 years (2022-10-06)	N/A
3 years (2021-10-06)	N/A
5 years (2019-10-10)	144.57%

Constellation Pharmaceuticals financials

Gross profit TTM	$0
Return on assets TTM	-22.41%
Return on equity TTM	-40.7%
Profit margin	0%
Book value	$7.88
Market Capitalization more info button	$1.6 billion

TTM: trailing 12 months

Constellation Pharmaceuticals share dividends

We're not expecting Constellation Pharmaceuticals to pay a dividend over the next 12 months.

Constellation Pharmaceuticals share price volatility

Over the last 12 months, Constellation Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Constellation Pharmaceuticals's is 2.5804. This would suggest that Constellation Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Constellation Pharmaceuticals overview

Constellation Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008.

Frequently asked questions

null
What percentage of Constellation Pharmaceuticals is owned by insiders or institutions?
Currently 1.528% of Constellation Pharmaceuticals shares are held by insiders and 109.699% by institutions. How many people work for Constellation Pharmaceuticals?
Latest data suggests 154 work at Constellation Pharmaceuticals. When does the fiscal year end for Constellation Pharmaceuticals?
Constellation Pharmaceuticals's fiscal year ends in December. Where is Constellation Pharmaceuticals based?
Constellation Pharmaceuticals's address is: 215 First Street, Cambridge, MA, United States, 02142 What is Constellation Pharmaceuticals's ISIN number?
Constellation Pharmaceuticals's international securities identification number is: US2103731061 What is Constellation Pharmaceuticals's CUSIP number?
Constellation Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 210373106